RT Journal Article
SR Electronic
T1 <em>Demonstrating</em> Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: <em>Evidence-Based</em> Risk Reduction
JF PDA Journal of Pharmaceutical Science and Technology
JO PDA J Pharm Sci Technol
FD Parenteral Drug Association (PDA)
SP 338
OP 345
DO 10.5731/pdajpst.2017.008524
VO 72
IS 3
A1 Ramnarine, Emma
A1 O'Donnell, Kevin
YR 2018
UL http://journal.pda.org/content/72/3/338.abstract
AB Product knowledge grows and evolves during the life of a product. In order to maintain a state of control and deliver product with consistent quality throughout its commercial life, continuous improvement and product lifecycle management become essential. The practical link between product and process knowledge, risk-based control strategies, and continual improvement and innovation can be made stronger through evidence-based risk reduction. This paper introduces the concept of evidence-based risk reduction within the continual improvement framework. It presents how regulatory relief and flexibility in post-approval change management and overall product lifecycle management can likely only be achieved via (1) effective application of science and risk-based concepts and (2) demonstrated effectiveness of the pharmaceutical quality system in assuring a state of control.